CA2906501A1 - Sequestrants of advanced glycation end product (age) precursors - Google Patents

Sequestrants of advanced glycation end product (age) precursors Download PDF

Info

Publication number
CA2906501A1
CA2906501A1 CA2906501A CA2906501A CA2906501A1 CA 2906501 A1 CA2906501 A1 CA 2906501A1 CA 2906501 A CA2906501 A CA 2906501A CA 2906501 A CA2906501 A CA 2906501A CA 2906501 A1 CA2906501 A1 CA 2906501A1
Authority
CA
Canada
Prior art keywords
alkyl
pharmaceutical composition
composition according
cycloalkyl
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906501A
Other languages
English (en)
French (fr)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus BESEV
Robert J. Miller
Andrew T. Papoulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA2906501A1 publication Critical patent/CA2906501A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2906501A 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors Abandoned CA2906501A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
US61/792,719 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
CA2906501A1 true CA2906501A1 (en) 2014-09-25

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906501A Abandoned CA2906501A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG10201707590XA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085377A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
EP1753861A4 (en) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares

Also Published As

Publication number Publication date
JP2022037143A (ja) 2022-03-08
IL241406A0 (en) 2015-11-30
PH12015502019A1 (en) 2016-01-11
HK1220607A1 (zh) 2017-05-12
BR112015023404A8 (pt) 2019-12-03
WO2014150873A1 (en) 2014-09-25
AR095593A1 (es) 2015-10-28
EA201591733A1 (ru) 2016-01-29
JP2020055850A (ja) 2020-04-09
AU2014235500A1 (en) 2015-11-05
EP2968403A1 (en) 2016-01-20
US20160024233A1 (en) 2016-01-28
AU2019201259A1 (en) 2019-03-14
UY35441A (es) 2014-10-31
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
MA38487A1 (fr) 2017-12-29
PE20151766A1 (es) 2015-12-11
CR20150545A (es) 2015-12-01
MX2015012843A (es) 2016-08-08
BR112015023404A2 (pt) 2017-07-18
US20180265613A1 (en) 2018-09-20
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
DOP2015000221A (es) 2015-12-15
CL2015002624A1 (es) 2016-03-11
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
JP2016512830A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
CN102858817B (zh) 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
CA2303447C (en) Cationic polymers as toxin-binding agents
AU2002257145B2 (en) Method for lowering serum glucose
CA2831392A1 (en) Conjugated lipomers and uses thereof
CN101448875A (zh) 鬼臼毒素类的高分子量结合体
WO2015081832A1 (zh) 炔基多臂聚乙二醇衍生物
JP2022037143A (ja) 終末糖化産物（ａｇｅ）前駆体の捕捉剤
CN108026271B (zh) 6配位铂络合物的高分子偶联物
US20100093973A1 (en) Poly(amino acid) compound having inhibitory activity on absorption of phosphorus and phosphorus absorption inhibitor
JP2020516675A (ja) ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
JP2017526767A (ja) 主鎖ポリアミン
OA17560A (en) Sequestrants of advanced glycation end product (AGE) precursors.
JP7088476B2 (ja) インドール及びその誘導体吸着剤
JP6429399B2 (ja) 抗プリオン化合物のマレイン酸塩及びその製造方法、並びにその医薬組成物
CN120398706A (zh) 具有组织黏附和ros响应性能的共聚物、载药纳米粒及其制备方法和应用
US10946028B2 (en) Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex
WO2025122826A1 (en) Hyaluronic acid-nonsteroidal anti-inflammatory drug conjugates for treating inflammation-mediated pathologies
HK1201525B (en) Amino acid derivatives functionalized on the n-terminal capable of forming drug incapsulating microspheres

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190219

FZDE Discontinued

Effective date: 20210913